Penumbra Inc
PEN
Company Profile
Business description
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Contact
1310 Harbor Bay Parkway
One Penumbra Place
AlamedaCA94502
USAT: +1 510 748-3200
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
4,700
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.40 | 69.70 | 0.77% |
| CAC 40 | 8,634.03 | 124.39 | 1.46% |
| DAX 40 | 26,077.62 | 448.38 | 1.75% |
| Dow JONES (US) | 53,076.02 | 590.99 | 1.13% |
| FTSE 100 | 10,846.16 | 21.89 | -0.20% |
| HKSE | 26,009.40 | 124.97 | 0.48% |
| NASDAQ | 25,775.21 | 401.36 | 1.58% |
| Nikkei 225 | 63,754.90 | 607.12 | -0.94% |
| NZX 50 Index | 13,774.93 | 75.65 | 0.55% |
| S&P 500 | 7,572.43 | 82.71 | 1.10% |
| S&P/ASX 200 | 9,019.30 | 70.30 | 0.79% |
| SSE Composite Index | 3,809.66 | 22.60 | -0.59% |